Diplomat Pharmacy (DPLO) Announces Quarterly Earnings Results, Misses Estimates By $0.21 EPS

Diplomat Pharmacy (NYSE:DPLO) released its earnings results on Tuesday. The company reported $0.01 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.22 by ($0.21), Fidelity Earnings reports. The company had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.42 billion. Diplomat Pharmacy had a net margin of 0.06% and a return on equity of 7.86%. Diplomat Pharmacy’s revenue for the quarter was up 22.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.01 earnings per share. Diplomat Pharmacy updated its FY18 guidance to $(0.10)-$0.03 EPS.

NYSE:DPLO traded down $5.54 during trading hours on Wednesday, hitting $14.80. 7,207,508 shares of the company traded hands, compared to its average volume of 987,505. The stock has a market cap of $1.57 billion, a P/E ratio of 17.62 and a beta of 0.95. Diplomat Pharmacy has a twelve month low of $13.31 and a twelve month high of $28.74. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.91 and a quick ratio of 0.63.

In other Diplomat Pharmacy news, Director Philip R. Hagerman sold 57,500 shares of the business’s stock in a transaction on Tuesday, September 11th. The shares were sold at an average price of $19.21, for a total value of $1,104,575.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Philip R. Hagerman sold 209,367 shares of the business’s stock in a transaction on Thursday, September 13th. The shares were sold at an average price of $19.07, for a total transaction of $3,992,628.69. The disclosure for this sale can be found here. 24.70% of the stock is owned by corporate insiders.

Several equities analysts recently commented on DPLO shares. ValuEngine cut shares of Diplomat Pharmacy from a “hold” rating to a “sell” rating in a research note on Wednesday, September 12th. Zacks Investment Research cut shares of Diplomat Pharmacy from a “hold” rating to a “sell” rating in a research note on Tuesday, October 23rd. Finally, Robert W. Baird cut shares of Diplomat Pharmacy from a “neutral” rating to an “underperform” rating and cut their target price for the company from $22.00 to $10.00 in a research note on Wednesday. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and six have given a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $26.10.

COPYRIGHT VIOLATION WARNING: “Diplomat Pharmacy (DPLO) Announces Quarterly Earnings Results, Misses Estimates By $0.21 EPS” was reported by WKRB News and is the property of of WKRB News. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://www.wkrb13.com/2018/11/08/diplomat-pharmacy-dplo-announces-quarterly-earnings-results-misses-estimates-by-0-21-eps.html.

About Diplomat Pharmacy

Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

Read More: Understanding the different types of bonds

Earnings History for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply